270 related articles for article (PubMed ID: 37208732)
1. Combined inhibition of histone deacetylase and cytidine deaminase improves epigenetic potency of decitabine in colorectal adenocarcinomas.
Tang Z; Liu L; Borlak J
Clin Epigenetics; 2023 May; 15(1):89. PubMed ID: 37208732
[TBL] [Abstract][Full Text] [Related]
2. Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study.
Molokie R; Lavelle D; Gowhari M; Pacini M; Krauz L; Hassan J; Ibanez V; Ruiz MA; Ng KP; Woost P; Radivoyevitch T; Pacelli D; Fada S; Rump M; Hsieh M; Tisdale JF; Jacobberger J; Phelps M; Engel JD; Saraf S; Hsu LL; Gordeuk V; DeSimone J; Saunthararajah Y
PLoS Med; 2017 Sep; 14(9):e1002382. PubMed ID: 28880867
[TBL] [Abstract][Full Text] [Related]
3. Demethylation by 5-aza-2'-deoxycytidine in colorectal cancer cells targets genomic DNA whilst promoter CpG island methylation persists.
Mossman D; Kim KT; Scott RJ
BMC Cancer; 2010 Jul; 10():366. PubMed ID: 20618997
[TBL] [Abstract][Full Text] [Related]
4. A pilot clinical trial of oral tetrahydrouridine/decitabine for noncytotoxic epigenetic therapy of chemoresistant lymphoid malignancies.
Hill B; Jagadeesh D; Pohlman B; Dean R; Parameswaran N; Chen J; Radivoyevitch T; Morrison A; Fada S; Dever M; Robinson S; Lindner D; Smith M; Saunthararajah Y
Semin Hematol; 2021 Jan; 58(1):35-44. PubMed ID: 33509441
[TBL] [Abstract][Full Text] [Related]
5. High cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effects.
Ebrahem Q; Mahfouz RZ; Ng KP; Saunthararajah Y
Oncotarget; 2012 Oct; 3(10):1137-45. PubMed ID: 23087155
[TBL] [Abstract][Full Text] [Related]
6. Tetrahydrouridine inhibits cell proliferation through cell cycle regulation regardless of cytidine deaminase expression levels.
Funamizu N; Lacy CR; Fujita K; Furukawa K; Misawa T; Yanaga K; Manome Y
PLoS One; 2012; 7(5):e37424. PubMed ID: 22616006
[TBL] [Abstract][Full Text] [Related]
7. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
[TBL] [Abstract][Full Text] [Related]
8. Butyrates and decitabine cooperate to induce histone acetylation and granulocytic maturation of t(8;21) acute myeloid leukemia blasts.
Gozzini A; Santini V
Ann Hematol; 2005 Dec; 84 Suppl 1():54-60. PubMed ID: 16228241
[TBL] [Abstract][Full Text] [Related]
9. Combination of azacytidine and curcumin is a potential alternative in decitabine-resistant colorectal cancer cells with attenuated deoxycytidine kinase.
Hosokawa M; Seiki R; Iwakawa S; Ogawara KI
Biochem Biophys Res Commun; 2021 Nov; 578():157-162. PubMed ID: 34571370
[TBL] [Abstract][Full Text] [Related]
10. 5-Aza-2'-deoxycytidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAF1 promoter demethylation.
Scott SA; Dong WF; Ichinohasama R; Hirsch C; Sheridan D; Sanche SE; Geyer CR; Decoteau JF
Leuk Res; 2006 Jan; 30(1):69-76. PubMed ID: 16043219
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and pharmacodynamics of an oral formulation of decitabine and tetrahydrouridine.
Lau H; Woost PG; Friedrich U; Clausen WHO; Jacobberger JW; Saunthararajah Y
Eur J Haematol; 2023 Sep; 111(3):345-355. PubMed ID: 37417197
[TBL] [Abstract][Full Text] [Related]
12. A pilot clinical trial of the cytidine deaminase inhibitor tetrahydrouridine combined with decitabine to target DNMT1 in advanced, chemorefractory pancreatic cancer.
Sohal D; Krishnamurthi S; Tohme R; Gu X; Lindner D; Landowski TH; Pink J; Radivoyevitch T; Fada S; Lee Z; Shepard D; Khorana A; Saunthararajah Y
Am J Cancer Res; 2020; 10(9):3047-3060. PubMed ID: 33042633
[TBL] [Abstract][Full Text] [Related]
13. Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine.
Lavelle D; Vaitkus K; Ling Y; Ruiz MA; Mahfouz R; Ng KP; Negrotto S; Smith N; Terse P; Engelke KJ; Covey J; Chan KK; Desimone J; Saunthararajah Y
Blood; 2012 Feb; 119(5):1240-7. PubMed ID: 22160381
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo.
Alcazar O; Achberger S; Aldrich W; Hu Z; Negrotto S; Saunthararajah Y; Triozzi P
Int J Cancer; 2012 Jul; 131(1):18-29. PubMed ID: 21796622
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and pharmacological evaluation of fluorinated tetrahydrouridine derivatives as inhibitors of cytidine deaminase.
Ferraris D; Duvall B; Delahanty G; Mistry B; Alt J; Rojas C; Rowbottom C; Sanders K; Schuck E; Huang KC; Redkar S; Slusher BB; Tsukamoto T
J Med Chem; 2014 Mar; 57(6):2582-8. PubMed ID: 24520856
[TBL] [Abstract][Full Text] [Related]
16. Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells.
Billam M; Sobolewski MD; Davidson NE
Breast Cancer Res Treat; 2010 Apr; 120(3):581-92. PubMed ID: 19459041
[TBL] [Abstract][Full Text] [Related]
17. Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy.
Chen MY; Liao WS; Lu Z; Bornmann WG; Hennessey V; Washington MN; Rosner GL; Yu Y; Ahmed AA; Bast RC
Cancer; 2011 Oct; 117(19):4424-38. PubMed ID: 21491416
[TBL] [Abstract][Full Text] [Related]
18. Synergistic Effect of Epigenetic Inhibitors Decitabine and Suberoylanilide Hydroxamic Acid on Colorectal Cancer In vitro.
Abou Najem S; Khawaja G; Hodroj MH; Rizk S
Curr Mol Pharmacol; 2019; 12(4):281-300. PubMed ID: 30868973
[TBL] [Abstract][Full Text] [Related]
19. Reexpression of tumor suppressor, sFRP1, leads to antitumor synergy of combined HDAC and methyltransferase inhibitors in chemoresistant cancers.
Cooper SJ; von Roemeling CA; Kang KH; Marlow LA; Grebe SK; Menefee ME; Tun HW; Colon-Otero G; Perez EA; Copland JA
Mol Cancer Ther; 2012 Oct; 11(10):2105-15. PubMed ID: 22826467
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic silencing of CHD5, a novel tumor-suppressor gene, occurs in early colorectal cancer stages.
Fatemi M; Paul TA; Brodeur GM; Shokrani B; Brim H; Ashktorab H
Cancer; 2014 Jan; 120(2):172-80. PubMed ID: 24243398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]